Evommune’s (EVMN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Evommune (NYSE:EVMN) in a report issued on Monday, MarketBeat Ratings reports.

A number of other equities research analysts have also issued reports on the stock. Raymond James Financial lowered shares of Evommune from a “strong-buy” rating to a “moderate buy” rating in a report on Monday, June 29th. William Blair lowered shares of Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Stifel Nicolaus started coverage on Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 price objective on the stock. Wall Street Zen lowered Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Morgan Stanley lowered their target price on Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.62.

Evommune Stock Performance

Shares of NYSE EVMN opened at $12.98 on Monday. The firm has a fifty day moving average of $16.37 and a 200 day moving average of $21.24. Evommune has a one year low of $10.47 and a one year high of $33.20. The firm has a market cap of $467.65 million and a PE ratio of -1.37.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. On average, equities analysts predict that Evommune will post -2.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arthur S. Kirsch acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was acquired at an average cost of $13.30 per share, with a total value of $133,000.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $133,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Luis C. Pena sold 7,438 shares of Evommune stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $22.71, for a total value of $168,916.98. Following the completion of the transaction, the chief executive officer owned 630,458 shares in the company, valued at $14,317,701.18. This trade represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 100,854 shares of company stock valued at $2,279,142. 31.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Evommune

Large investors have recently made changes to their positions in the stock. Strs Ohio purchased a new stake in Evommune during the 1st quarter worth about $41,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Evommune during the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company acquired a new position in Evommune in the 4th quarter valued at $179,000. XTX Topco Ltd purchased a new position in shares of Evommune during the 4th quarter worth about $321,000. Finally, Oxford Asset Management LLP purchased a new position in Evommune during the fourth quarter worth approximately $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.